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CC BY-NC-ND license (http://creativeAbstract Tumour heterogeneity is a phenomenon where each cell that makes up a tumour,
contains mutations that differ from that of other cells in the tumour. The clonal evolution
and cancer stem cell theories of cancer formation, have been used to explain tumour hetero-
geneity. The theories both point to the existence of cells within a tumour that are capable of
initiating the tumour in a different location. While the clonal evolution theory argues that all
cells within a tumour possess this ability, the cancer stem cell theory argues that only a few
cells (cancer stem cells or CSCs) within the tumour possess this ability to seed the tumour in
a different location. Data supporting the cancer stem cell theory is accumulating. Researchers
have targeted these CSCs therapeutically, hypothesizing that since these CSCs are the ‘drivers’
of tumour progression, their death may inhibit tumour progression. This was foiled by tumour
cell plasticity, a phenomenon whereby a non-CSC spontaneously de-differentiates into a CSC.
Researchers are now working on combinations that kill both CSCs and non-CSCs as well as drugs
that prevent non-CSC-to-CSC transition. This review concisely describes CSCs and how they
contribute to the difficulty in treating cancer.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Cancer is a name used to describe a large and diverse group
of diseases most notably characterized by a rapid increase
in the growth and proliferation of certain cells (that have
acquired genomic mutations) and a resultant tumour mass.
This malignant tumour mass is distinguished from benign
tumours because of the ability to metastasize, i.e. spread
to other distant organs.ity of Chongqing Medical
16.01.001
ng Medical University. Production
commons.org/licenses/by-nc-nd/How cancer originates
Cancer originates from a single mutation within the genome
of a cell. Subsequent accumulation of more mutations can
turn a normal cell into an aberrant cell.1 A mutation in
which a tumour suppressor such as p53, Rb or p16INK4a/
p14ARF is knocked down, or an oncogene such as Ras
become constitutively active, leads to excessive prolifera-
tion of the cell,2e4 and with each cell division, the chances
of cells acquiring more mutations increases. Eventually,
cells accumulate enough mutations to trigger endless
growth and tumour formation.3and hosting by Elsevier B.V. This is an open access article under the
4.0/).
8 PerspectivesThe difficulty in treating cancer
Generally, cancer is not noticed by patients until it has gotten
to a late stage e metastasis. At this stage, there is not much
doctors can do. Doctors may try to remove the tumour mass
surgically and administer chemotherapy and radiation, but
apart from the side effects these techniques have on normal
cells, chemotherapy is not very effective in completelywiping
out cancer cells, because in a given tumour, there are
different types of cancer cells with different kinds of muta-
tions. Indeed, cancer tumours do not contain homogenous
cancer populations, rather they contain heterogeneous
cancer populations.5 This is one reason for the difficulty in
treating cancer, as it is not easy to administer a drug combi-
nation that targets each of the cancer cells in a tumour, due to
their genomic diversity. This concept is known as tumour
heterogeneity (diversity in the cancer cells that make up a
tumour). Based on literature review, tumour heterogeneity
seems to be themain causeof cancer relapse and resistance to
chemotherapy e the biggest challenges in cancer treatment.
Origin of tumour heterogeneity
Tumour heterogeneity is as a result of both intrinsic and
extrinsic factors. Intrinsic factors include genetic and
epigenetic mutations that contribute to tumorigenicity
while extrinsic factors include the microenvironment
around the tumour that interacts with the tumour to aid its
progression.6
Theories of tumour heterogeneity
Researchers have put forward theories to explain the origin
of tumour heterogeneity from the intrinsic point of view. In
this review, I will discuss the two prominent theories: the
clonal evolution theory and the cancer stem cell theory.
Both theories have data supporting them, but not without
inconsistencies.
Clonal evolution theory
This theory is based on Darwin’s theory of evolution.
According to this theory, an initial mutation in a cell is
passed on to each of the daughter cells and with each
subsequent division, these daughter cells acquire and
accumulate more and more transforming mutations. Over
time, the cells with the most mutations that cause a growth
and proliferation advantage are clonally expanded, leading
to the formation of a tumour mass with clones of different
aberrant cells.7 The evidence for this theory came from
observations of different tumours. It was found that all the
cancer cells in a given tumour had one or few founder mu-
tations in common, while some mutations were specifically
found in individual cancer cells. This implies that the cancer
cells evolved from one original mutated cancer cell.7
Cancer stem cell theory
This is a more recent theory based on the observation that
there are a few cells within many, if not all tumour massesthat display stem cell-like properties namely: the ability to
self-renew, as well as the ability to give rise to all the
different types of cancer cells within that tumour.5 Accord-
ing to this theory, these cancer stem cells (CSCs) can be
placed at the apex of a hierarchy, and can undergo either
symmetric or asymmetric division (Fig. 1). When they
undergo symmetric division, they either produce two iden-
tical daughter cells that are replicas of them (CSCs) e this is
known as ‘self-renewal’; or two identical daughter cells that
are progenitors (non-CSCs) and can subsequently differen-
tiate to form any of the types of cancer cells within the
tumour. There is also asymmetric division in which the stem
cell divides to produce two non-identical daughter cells. One
is a replica of the stem cell (CSC), while the other is a
progenitor cell (non-CSC) which can go on to differentiate
into any cancer cell type within the tumour (with contribu-
tion from stimuli produced by the microenvironment).5
It is very likely that the two theories of tumour hetero-
geneity may apply to human cancers of different types, and
in some tumours, both models may apply.
Evidence for the existence of cancer stem cells
In 1997, Bonnet and Dick8 showed that a specific group of
leukaemic cells expressing CD34 on their cell surface and
lacking CD38 were capable of initiating new tumours when
injected into immunosuppressed NOD/SCID mice. Cancer
cells with this type of ability have also been demonstrated
to be present in solid human tumours.9 Importantly, these
CSCs capable of initiating new tumours, have been shown to
be relatively few within the tumour and this has raised the
possibility that the current drugs used in managing cancer,
destroy other cells within the tumour but not the CSCs
(because they are relatively few), hence these CSCs
regenerate the tumour once the therapy is discontinued,
leading to relapse as well as resistance to the therapeutics
previously used.5
This concept is an important difference between the
clonal evolution and the CSC theories, i.e according to the
CSC theory, only a subpopulation of the cancer cells within
the tumour, are cancer stem cells and are capable of
initiating a tumour in a different location (e.g during
metastasis or xenotransplantation). Therefore, the CSCs
are said to be the drivers of tumour progression, even
though they are just a minority. The clonal evolution theory
however, claims that all cancer cells within a tumour, have
the ability to form a new tumour mass in a different loca-
tion and each tumour mass consists of numerous clones of
different cancer cells harbouring different genetic muta-
tions; hence, the heterogeneous nature of malignant
tumours.5
Challenges of the cancer stem cell theory
The cancer stem cell theory, like many other scientific
theories has been subjected to critique. One major
drawback of the CSC model is the lack of definitive surface
markers. The markers seen on CSCs tend to be similar to
those on normal adult stem cells, normal cancer cells or
normal tissues10e13 and also, the markers seen on different
Fig. 1 Cancer stem cell hierarchy. According to the cancer stem cell theory, a cancer stem cell is at the top of a hierarchy. It has
the ability to self-renew (arrow 1), i.e. give rise to a daughter cell that is an exact replica of itself. It also has the ability to give rise to
any of the cancer cell types within a tumour. It does this by dividing to form a daughter cell (non-CSC) that can subsequently divide
severally before differentiating into diverse cancer cells (arrows 2ae5d, excluding arrow 2b). Tumour cell plasticity also occurs, in
which a progenitor cell (non-CSC) spontaneously de-differentiates into a CSC (arrow 2b). It is thus able to initiate a new tumour.
Perspectives 9CSCs tend to differ from one another.13 Researchers have
argued that there should be specific surface markers on
CSCs that can be targeted specifically without the risk of
damaging normal adult cells; and also, certain CSC
markers should be expressed on many types of CSCs.13 In
reality, it is not unrealistic to find CSCs sharing surface
markers with normal adult stem cells, since it has been
proposed that CSCs originate from mutations in normal
stem cells.13 Also, tumour heterogeneity is useful in
explaining the reason why CSCs of a particular organ
express different markers in different locations (for
instance in different human hosts).
Effect of selective targeting of cancer stem
cells
Currently, researchers are developing drugs that take
tumour heterogeneity into account, as this is obviously a
key reason for the mass failure in cancer therapy that has
been recorded over the years. Based on the cancer stem
cell model, a scan of 16,000 drugs was carried out, and
one of them (Salinomycin) was found to be highly effective
in killing breast CSCs, while sparing non-CSCs.14 The idea
behind this was that, since it is CSCs that drive tumour
progression, then wiping out CSCs will lead to shrinkage of
the tumour mass. Indeed, the results were very close to
expectations, but not without problems. It has been foundthat under conditions of genetic manipulation, mammary
non-CSCs are able to utilize the mechanism of epithelial-
to-mesenchymal transition (EMT) in order to undergo
de-differentiation and become mammary CSCs once
again.5,15,16 This is known as tumour cell plasticity.
Another mechanism by which mammary non-CSCs can
spontaneously de-differentiate into mammary CSCs in vivo
without any genetic manipulation, has subsequently been
described17 e See Fig. 1. Furthermore, tumour cell plas-
ticity has been demonstrated in JARID1B-negative mela-
noma cells which spontaneously revert into a JARID1B-
positive state, thereby giving rise to an increase in
tumour growth.18 Hence, administering drugs like Salino-
mycin and Abamectin, (which specifically destroy CSCs,
while sparing non-CSCs) might lead to tumour shrinkage
initially, but with time the tumour will relapse if one or
more of the non-CSCs is able to de-differentiate into a
CSC, and worse still, the resulting tumour will most likely
be resistant to the chemotherapy previously used.5Future strategies
Future research should be aimed at providing new drug
combinations that kill both CSCs and non-CSCs or at least
drugs that prevent non-CSC-to-CSC transition can be
combined with drugs that selectively destroy CSCs. This
may hopefully be more effective in the long run.
10 PerspectivesConclusion
Cancer is extremely difficult to treat successfully, because
there are too many things to be targeted therapeutically
at the same time. Targeting one thing while leaving out
the other, could lead to an initial tumour shrinkage, with
an eventual relapse of the cancer and consequent drug
resistance. The cancer stem cell theory is helping to
advance the state of research, but not without its inherent
challenges and limitations. Currently, research is on-going
to develop combination therapies that will destroy cancer
cells, prevent relapse, as well as have minimal side
effects. This may seem to be ambitious, considering the
complex nature of cancer, but I believe that, the remedy
for individual cancers is nearer to us now than it ever was
before!
References
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;
100:57e70.
2. Sherr CJ. Principles of tumor suppression. Cell. 2004;116:
235e246.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell. 2011;144:646e674.
4. Weinberg RA. The Biology of Cancer. 2nd ed. New York, USA:
Garland Science, Taylor and Francis Group LLC; 2013.
5. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and
heterogeneity in cancer. Clin Chem. 2013;59:168e179.
6. Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K.
Cancer stem cells and the tumour microenvironment: interplay
in tumour heterogeneity. Connect Tissue Res. 2015;56:
414e425.
7. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer
drug resistance. Lancet Oncol. 2012;13:e178ee185.8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized
as a hierarchy that originates from a primitive hematopoietic
cell. Nat Med. 1997;3:730e737.
9. Visvader JE, Lindeman GJ. Cancer stem cells: current status
and evolving complexities. Cell Stem Cell. 2012;10:717e728.
10. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell
Biol. 2013;15:338e344.
11. Karsten U, Goletz S. What makes cancer stem cell markers
different? SpringerPlus. 2013;2:301.
12. Liu Y, Nenutil R, Appleyard MV, et al. Lack of correlation of
stem cell markers in breast cancer stem cells. Br J Cancer.
2014;110:2063e2071.
13. Wang T, Shigdar S, Gantier MP, et al. Cancer stem cell targeted
therapy: progress amid controversies. Oncotarget. 2015;6:
44191e44206.
14. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage
or reality? Nat Med. 2009;15:1010e1012.
15. Mani SA, Guo W, Liao MJ, et al. The epithelial-to-mesenchymal
transition generates cells with properties of stem cells. Cell.
2008;133:704e715.
16. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A.
Generation of breast cancer stem cells through epithelial-
mesenchymal transition. PLoS One. 2008;3:e2888.
17. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and
neoplastic nonstem cells can spontaneously convert to a stem-
like state. PNAS. 2011;108:7950e7955.
18. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily
distinct subpopulation of slow-cycling melanoma cells is
required for continuous tumor growth. Cell. 2010;141:583e594.
Sylvia Oghogho Iseghohi
Department of Biochemistry, University of Benin, P.M.B.
1154, Edo State, Nigeria
E-mail address: sylvia.iseghohi.13@ucl.ac.uk
10 December 2015
